CapForce (CFOR)
OTHER OTC:CFOR
Top Page
No summary available
Positive Factors
Revenue Growth
A 52% revenue growth rate indicates strong demand for OpGen's diagnostic products, suggesting robust market positioning and potential for sustained growth.
Negative Factors
Financial Sustainability
Reliance on external funding and high leverage can threaten financial stability, limiting the company's ability to invest in growth and innovation.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
A 52% revenue growth rate indicates strong demand for OpGen's diagnostic products, suggesting robust market positioning and potential for sustained growth.
Read all positive factors
CapForce (CFOR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$286.19M
Dividend YieldN/A
Average Volume (3M)1.29K
Price to Earnings (P/E)―
Beta (1Y)-9612.18
Revenue Growth610.97%
EPS GrowthN/A
CountryUS
Employees1
SectorFinancial
Sector Strength70
IndustryFinancial - Capital Markets
Share Statistics
EPS (TTM)N/A
Shares Outstanding12,178,278
10 Day Avg. Volume0
30 Day Avg. Volume1,287
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.38
Price to Sales (P/S)0.53
P/FCF Ratio-0.57
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue18.46
Enterprise Value/Gross Profit18.66
Enterprise Value/Ebitda23.02
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CapForce Business Overview & Revenue Model
Company Description
CapForce Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company's products include Unyvero application cartrid...
How the Company Makes Money
OpGen generates revenue primarily through the sale of its diagnostic products and services. The company's revenue model is based on selling its molecular diagnostic tests, such as the Acuitas AMR Gene Panel and the Unyvero platform, to hospitals, ...
CapForce Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.00M | 5.20M | 3.42M | 2.61M | 4.31M | 4.21M |
| Gross Profit | 8.90M | 4.99M | -90.69K | -817.00K | 1.46M | 365.95K |
| EBITDA | 7.22M | 12.35M | -29.51M | -32.38M | -20.39M | -20.34M |
| Net Income | 6.84M | 11.99M | -32.67M | -37.28M | -34.81M | -26.21M |
Balance Sheet | ||||||
| Total Assets | 12.64M | 9.86M | 1.88M | 25.83M | 71.67M | 49.75M |
| Cash, Cash Equivalents and Short-Term Investments | 414.21K | 1.31M | 1.15M | 7.44M | 36.08M | 13.36M |
| Total Debt | 3.77M | 2.11M | 13.04M | 14.84M | 25.18M | 22.85M |
| Total Liabilities | 2.48M | 2.48M | 13.44M | 18.25M | 30.45M | 28.56M |
| Stockholders Equity | 10.16M | 7.38M | -11.56M | 7.58M | 41.22M | 21.19M |
Cash Flow | ||||||
| Free Cash Flow | -1.21M | -4.87M | -15.12M | -21.04M | -23.46M | -23.53M |
| Operating Cash Flow | -1.21M | -4.87M | -14.32M | -20.45M | -21.48M | -23.40M |
| Investing Cash Flow | 0.00 | 0.00 | -800.41K | -590.77K | -1.98M | -1.06M |
| Financing Cash Flow | -98.31K | 5.03M | 8.37M | -6.74M | 47.45M | 34.09M |
CapForce Technical Analysis
Negative
23.50
Price Trends
24.06
Negative
18.08
Positive
Market Momentum
-0.02
Positive
46.81
Neutral
87.31
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CFOR, the sentiment is Negative. The current price of 23.5 is above the 20-day moving average (MA) of 23.30, below the 50-day MA of 24.06, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 46.81 is Neutral, neither overbought nor oversold. The STOCH value of 87.31 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CFOR.
CapForce Risk Analysis
CapForce disclosed 19 risk factors in its most recent earnings report. CapForce reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CapForce Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
| ― | $286.19M | ― | 77.64% | ― | 610.97% | ― | |
57 Neutral | $49.62M | -101.61 | -10.07% | ― | 30.95% | 59.67% | |
57 Neutral | $174.96M | -2.82 | -9.93% | ― | 5.44% | 72.17% | |
56 Neutral | $131.31M | -1.46 | -302.55% | ― | 22.29% | 31.93% | |
50 Neutral | $12.87M | -0.32 | -56.22% | ― | -13.84% | 88.80% | |
47 Neutral | $27.32M | -1.17 | 76.82% | ― | 14.48% | 36.83% |
* Financial Sector Average
CFOR
CapForce
23.50
19.51
488.97%
VNRX
VolitionRX
0.17
-0.31
-64.46%
PRPO
Precipio
27.82
22.42
415.19%
BNGO
BioNano Genomics
1.16
-3.24
-73.64%
BNR
Burning Rock Biotech
16.25
13.22
436.30%
BDSX
Biodesix
13.32
1.92
16.84%
CapForce Corporate Events
Executive/Board ChangesPrivate Placements and Financing
OpGen amends financing deal and announces president’s resignation
Neutral
Dec 23, 2025
On December 17, 2025, OpGen, Inc. further amended its existing financing arrangement with AEI Capital Ltd. by signing a Supplemental Letter that extends the company’s ability to sell up to $9.0 million of its common stock to the investor und...
Executive/Board Changes
OpGen Appoints New CEO Christian-Laurent Bonte
Neutral
Dec 5, 2025
On December 1, 2025, OpGen announced the resignation of John Tan Honjian from his role as Chief Executive Officer, although he will remain as Chairman of the Board. Christian-Laurent Bonte was appointed as the new CEO, bringing extensive investmen...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―